Johnson & Johnson Pulls Plug On Large Late-Stage Study Of RSV Vaccine Candidate; GSK, Pfizer Shots Are Under FDA Review

  • After reviewing its portfolio to prioritize and assessing the respiratory syncytial virus (RSV) vaccine landscape, Janssen, a unit of Johnson & Johnson JNJ, will exit its investigational RSV adult vaccine program and discontinue its Phase 3 EVERGREEN study.
  • The Phase 3 study estimated to enroll over 27,000 participants.
  • Pfizer Inc PFE and GSK plc GSK have their RSV vaccine candidates under FDA review, with a decision expected in May to use their shots in adults 65 and older. 
  • Pfizer also expects the FDA to decide by August whether the shot can be used in infants and pregnant women.
  • The RSV vaccine market is estimated to be over $5 billion and could exceed $10 billion by 2030, Reuters reported, citing analysts.
  • Data from a Phase 2b CYPRESS trial showed that the vaccine generated 80% protection against lower respiratory infections in older adults. By then, it had already initiated the large Phase 3 trial.
  • The investigational RSV adult vaccine also demonstrated an efficacy of 70% against any symptomatic RSV-associated acute respiratory infection.
  • Price Action: JNJ shares are up 0.69% at $152.86 on the last check Wednesday.
  • Photo Via Company
Posted In: BiotechLarge CapNewsHealth CareMediaGeneralBriefs